Clinical trial · Observational
Expression and Clinical Significance of IGHD in Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background ： Pancreatic cancer is the most malignant tumor in the digestive system, with low level of early diagnosis and poor prognosis. There is a lack of high sensitive and specific molecular markers in the diagnosis, treatment and prognosis of pancreatic cancer. Objective： To explore the expression of IGHD in pancreatic cancer and its correlation with clinical parameters, and to explore its prognostic value in patients with pancreatic cancer. Methods： In this study, qRT-PCR was used to detect IGHD expression in peripheral blood. The expression of IGHD in pancreatic cancer and healthy individuals was compared. The PCR results were combined with clinical data of patients. To compare the expression of IGHD in different pancreatic cancer stages and evaluate whether IGHD expression in peripheral blood can be a potential biomarker for the diagnosis of pancreatic cancer, chi-square test was used to analyze the factors influencing the expression level of IGHD. Kaplan-Meier was used to analyze patient prognosis, and further Cox regression analysis was used to analyze the factors influencing patient prognosis and independent risk factors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gene Expression | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pathological | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- pancreatic cancer patients
- description
- pathologically confirmed pancreatic cancer patients
- interventionNames
- Other: Pathological
- label
- healthy people
- description
- people without no neoplastic lesions and other organic diseases
Primary outcomes (1)
- measure
- High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.
- timeFrame
- 2022.4-2023.10
- description
- IGHD was highly expressed in pancreatic cancer patients , but low in the healthy cancer-free patients. Patients with high expression of IGHD had lower prognosis. High expression of IGHD, T stage (T3T4), lymphatic metastasis and distant metastasis are independent risk factors for poor prognosis in patients with pancreatic cancer. Expression level of IGHD in peripheral blood cells is a potential biomarker for the diagnosis of pancreatic cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pathologically confirmed pancreatic cancer Exclusion Criteria: * noperable patients * other malignant tumors
References
Publications (0)
Data not yet available